Delivery of GENE-EDITING constructs could be very lucrative for PAB . Something not priced in the share price regarding future potential.
Comment by PAB in 2022
Patrys could also become a pioneer in the emerging gene-editing payload delivery space, giving it a lead in the gene therapy space, which is expected to see 1,500% growth by 2027, he added.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more